Lv21
150 积分 2021-03-04 加入
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
10天前
已完结
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?
10天前
已完结
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
10天前
已完结
Current and Future Biomarkers in the Management of Renal Cell Carcinoma
12天前
已完结
Established and emerging biomarkers of immunotherapy in renal cell carcinoma
12天前
已完结
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
27天前
已完结
Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma
1个月前
已完结
The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma
1个月前
已完结
Renal cell carcinoma
2个月前
已完结
Molecular subtypes as potential biomarkers in renal cell carcinoma
2个月前
已完结
皖公网安备34019202002308
